Efficacy and Tolerance of First-Line Afatinib in Elderly NSCLC Patients with EGFR Mutations in Vietnam: A Multicenter Real-World Study.

Among patients initiating treatment at doses below 40 mg/day, a trend toward reduced mTTF was noted (16.1 months compared to 18.4 months); however, this difference did not reach statistical significance (p=0.341).

also in 111,027 other papers